MX2010001302A - Avidina oxidada con tiempo de residencia elevado en tejidos tratados. - Google Patents
Avidina oxidada con tiempo de residencia elevado en tejidos tratados.Info
- Publication number
- MX2010001302A MX2010001302A MX2010001302A MX2010001302A MX2010001302A MX 2010001302 A MX2010001302 A MX 2010001302A MX 2010001302 A MX2010001302 A MX 2010001302A MX 2010001302 A MX2010001302 A MX 2010001302A MX 2010001302 A MX2010001302 A MX 2010001302A
- Authority
- MX
- Mexico
- Prior art keywords
- avidin
- oxidation
- sub
- avidins
- treated tissues
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Optics & Photonics (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención describe avidinas químicamente modificadas que tienen una mayor permanencia en tejidos tratados, en comparación con la avidina de tipo silvestre. La oxidación de la avidina se efectúa por incubación de peryodato en presencia del ligando de baja afinidad HABA, la cual, ocupa los sitios de unión con la biotina, impide la desnaturalización de la proteína durante la etapa de oxidación. La oxidación de peryodato genera grupos CHO de la apertura del anillo de manosa de avidina que, una vez inyectados, reaccionan con residuos de NH2 del tejido y forman bases de Schiff estables. Las avidinas fijadas mantienen la capacidad de ligar agentes biotinilados dotados de actividad terapéutica, como las biotinas radiomarcadas, células madre y células somáticas, útiles para braquiterapia, como la Terapia con Radionucleidos por Avidinación lntraoperatoria (IARTO(r)), o enfermedades degenerativas o genéticas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07113733 | 2007-08-02 | ||
| EP08157473 | 2008-06-03 | ||
| PCT/EP2008/059260 WO2009016031A1 (en) | 2007-08-02 | 2008-07-16 | Oxidized avidin with high residency time in the treated tissues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010001302A true MX2010001302A (es) | 2010-03-01 |
Family
ID=39734214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010001302A MX2010001302A (es) | 2007-08-02 | 2008-07-16 | Avidina oxidada con tiempo de residencia elevado en tejidos tratados. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8562947B2 (es) |
| EP (1) | EP2185203B1 (es) |
| JP (1) | JP5577248B2 (es) |
| KR (1) | KR101544628B1 (es) |
| CN (1) | CN101772353B (es) |
| AR (1) | AR067771A1 (es) |
| AU (1) | AU2008281901B2 (es) |
| BR (1) | BRPI0815050B8 (es) |
| CA (1) | CA2694391C (es) |
| DK (1) | DK2185203T3 (es) |
| EA (1) | EA017017B1 (es) |
| ES (1) | ES2625815T3 (es) |
| HK (1) | HK1145290A1 (es) |
| HR (1) | HRP20170735T1 (es) |
| HU (1) | HUE032093T2 (es) |
| IL (1) | IL203321A (es) |
| LT (1) | LT2185203T (es) |
| MX (1) | MX2010001302A (es) |
| MY (1) | MY155347A (es) |
| NZ (1) | NZ582711A (es) |
| PL (1) | PL2185203T3 (es) |
| PT (1) | PT2185203T (es) |
| SG (1) | SG183076A1 (es) |
| SI (1) | SI2185203T1 (es) |
| TW (1) | TWI441650B (es) |
| WO (1) | WO2009016031A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2591524C2 (ru) * | 2010-12-28 | 2016-07-20 | Джапан Тобакко Инк. | Модифицированный тамавидин |
| BR112014002593B1 (pt) * | 2011-08-02 | 2022-11-29 | Alfasigma S.p.A | Composição farmacêutica de avidina oxidada apropriada para inalação e kits relacionados |
| JP2014001204A (ja) * | 2012-05-23 | 2014-01-09 | Kumamoto Univ | 腫瘍細胞選択的抗がん剤 |
| WO2014107566A1 (en) | 2013-01-04 | 2014-07-10 | Massachusetts Institute Of Technology | Surface binding of nanoparticle based drug delivery to tissue |
| EP3316871A4 (en) | 2015-06-30 | 2019-02-20 | The Trustees of Columbia University in the City of New York | TALKED COMPOSITION AND USES THEREOF |
| WO2017201436A1 (en) * | 2016-05-19 | 2017-11-23 | University Of Miami | Targeted delivery of therapeutic agents and imaging reagents to pancreatic cancer cells |
| CN112703401A (zh) * | 2018-09-25 | 2021-04-23 | 美国西门子医学诊断股份有限公司 | 用于从使用缀合的分子阱的测定除去生物素干扰的方法和组合物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09506594A (ja) * | 1993-12-07 | 1997-06-30 | ネオルクス コーポレーション | プレターゲティング方法及び化合物 |
| US5716594A (en) * | 1994-06-06 | 1998-02-10 | The Jmde Trust | Biotin compounds for targetting tumors and sites of infection |
| US8021667B2 (en) * | 1994-11-16 | 2011-09-20 | Macfarlane Burnet Institute For Medical Research And Public Health Ltd | Compositions for immunotherapy and uses thereof |
| WO2000027814A1 (en) * | 1998-11-10 | 2000-05-18 | Yeda Research And Development Co. Ltd. | Avidin derivatives and uses thereof |
| US7001994B2 (en) * | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
| US20040101901A1 (en) * | 2002-11-27 | 2004-05-27 | Piotr Tabaczewski | Novel lipophilic complexes for insertion of receptors into lipid membranes |
| ITRM20030196A1 (it) * | 2003-04-24 | 2004-10-25 | Sigma Tau Ind Farmaceuti | Uso di reagenti per la preparazione di un medicamento |
-
2008
- 2008-07-16 SG SG2012054938A patent/SG183076A1/en unknown
- 2008-07-16 HU HUE08775109A patent/HUE032093T2/en unknown
- 2008-07-16 NZ NZ582711A patent/NZ582711A/en unknown
- 2008-07-16 WO PCT/EP2008/059260 patent/WO2009016031A1/en active Application Filing
- 2008-07-16 MY MYPI2010000136A patent/MY155347A/en unknown
- 2008-07-16 CN CN2008801016692A patent/CN101772353B/zh active Active
- 2008-07-16 EA EA201070216A patent/EA017017B1/ru unknown
- 2008-07-16 KR KR1020107004513A patent/KR101544628B1/ko active IP Right Grant
- 2008-07-16 LT LTEP08775109.5T patent/LT2185203T/lt unknown
- 2008-07-16 DK DK08775109.5T patent/DK2185203T3/da active
- 2008-07-16 AU AU2008281901A patent/AU2008281901B2/en active Active
- 2008-07-16 EP EP08775109.5A patent/EP2185203B1/en active Active
- 2008-07-16 US US12/670,925 patent/US8562947B2/en active Active
- 2008-07-16 PL PL08775109T patent/PL2185203T3/pl unknown
- 2008-07-16 ES ES08775109.5T patent/ES2625815T3/es active Active
- 2008-07-16 CA CA2694391A patent/CA2694391C/en active Active
- 2008-07-16 PT PT87751095T patent/PT2185203T/pt unknown
- 2008-07-16 JP JP2010518601A patent/JP5577248B2/ja active Active
- 2008-07-16 SI SI200831808A patent/SI2185203T1/sl unknown
- 2008-07-16 BR BRPI0815050A patent/BRPI0815050B8/pt active IP Right Grant
- 2008-07-16 MX MX2010001302A patent/MX2010001302A/es active IP Right Grant
- 2008-07-18 TW TW097127328A patent/TWI441650B/zh active
- 2008-08-01 AR ARP080103343A patent/AR067771A1/es active IP Right Grant
-
2010
- 2010-01-14 IL IL203321A patent/IL203321A/en active IP Right Grant
- 2010-12-16 HK HK10111803.2A patent/HK1145290A1/xx unknown
-
2017
- 2017-05-16 HR HRP20170735TT patent/HRP20170735T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1145290A1 (en) | Oxidized avidin with high residency time in the treated tissues | |
| WO2005005601A3 (en) | Compositions and methods for treating and diagnosing cancer | |
| MXPA06012500A (es) | Compuestos para el tratamiento de la enfermedad de alzheimer y para la inhibicion de la produccion del peptido beta-amiloideo. | |
| WO2006120573A3 (en) | Heterocyclic n-oxides as hypoxic selective protein kinase inhibitors | |
| WO2005117954A3 (en) | Compositions and methods for treatment of neovascular diseases | |
| WO2006044860A3 (en) | Thiadiazole compounds and methods of use | |
| EA200602191A1 (ru) | 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения | |
| WO2003020698A3 (en) | Protein tyrosine kinase inhibitors | |
| WO2005076979A3 (en) | Diagnosis and therapeutics for cancer | |
| HK1103363A1 (en) | Treatment of glycogen storage diseases type ii ii | |
| WO2004050026A3 (en) | Compositions and methods for treating prostate cancer | |
| TW200613305A (en) | Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one | |
| WO2007022470A3 (en) | Methods and compositions for treating neurological disease | |
| WO2006047032A3 (en) | Indole compounds useful as serotonin selective agents | |
| MXPA03011466A (es) | Macrociclos utiles en tratamiento de enfermedades de alzheimer. | |
| WO2001021771A3 (en) | Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents | |
| TW200640944A (en) | VGF polypeptides and methods of treating VGF-related disorders | |
| WO2007098047A3 (en) | Methods and compositions for the treatment of parkinson's disease | |
| WO2006113925A3 (en) | Composition and use of phyto-percolate for treatment of disease | |
| WO2004073375A8 (en) | Podophyllotoxin derivatives as antitumor agents | |
| WO2005103034A8 (en) | Novel piperidine substituted diaminothiazoles | |
| MXPA02000680A (es) | Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf. | |
| TW200727904A (en) | Method of administration for 5-(2-chlorophenyl)-1,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo[3,4-b][1,4]benzodiazepine | |
| WO2004110377A3 (en) | Porphyrins and metalloporphyrins for inhibiting heme iron uptake | |
| AU4584100A (en) | Morphinoid compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |